Alpelisib is a phosphatidylinositol 3-kinase inhibitor approved by the US Food and Drug Administration for the treatment of hormone receptor–positive metastatic breast cancer with PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) mutation. In recent years a number of adverse effects have been observed to be associated with this therapy, the most...
Objectives: This study explored the prevalence of nonadherence and preferences for breast cancer (BRC) and colorectal cancer (CRC) screening among hospitalized women with and without obesity who were cancer-free at baseline. In addition, the study evaluated risk factors associated with nonadherence among hospitalized women with obesity. Methods: A prospective interventional...
Objectives: Preoperative chemotherapy produces tumor shrinkage in most patients with locally advanced breast cancer, including some pathological complete responses (pCRs). We attempted this using a much less toxic sequential regimen, given with concurrent bevacizumab. Methods: Patients with locally advanced breast cancer received 3 intravenous doses each of preoperative sequential liposome...
Membership grants access to journals, courses and a slew of premium benefits.
Please consider supporting us by choosing an option below:
View Membership Options Make A Tax-Deductable Donation
No Thanks, take me to the site and don't show me this again.